Rheumatology

Your Article Summary

See Latest Articles

Tacrolimus therapy for systemic lupus erythematosus without renal involvement: a preliminary retrospective study
Modern Rheumatology, 09/02/09

Kusonoki Y et al. – Tacrolimus might be a treatment option for active SLE without renal involvement.

• 10 SLE patients with symptoms such as arthritis and erythema, but no active nephritis, were treated with tacrolimus.
• Tacrolimus was administered at doses of 1–3 mg daily, and efficacy was assessed from the SLE Disease Activity Index (SLEDAI) after 1 year

• 8 patients completed 1 year of treatment, and significant improvement of disease activity was observed in 6 patients
• The mean dose of prednisolone also decreased significantly, from 16.8 ± 8.6 to 9.3 ± 4.6 mg/day

Today in Clinical Pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: Clinicopathological features of 24 patients
Journal of Rheumatology, 11/09/09

Treatment of polymyalgia rheumatica
Archives of Internal Medicine, 11/10/09

Osteoarthritis: A review of treatment options
Geriatrics, 10/21/09

See All of Clinical Pharmacology

Today in Rheumatoid Arthritis...keeping you current

Receive free subspecialty "5-minute updates" via email

Treatment of polymyalgia rheumatica
Archives of Internal Medicine, 11/10/09

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor [alpha] therapies: Does the risk change with the time since start of treatment?
Arthritis & Rheumatism, 11/05/09

Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study
Arthritis Care and Research , 11/03/09

See All of Rheumatoid Arthritis